Does the media prefer ERAS or ASND?

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Ascendis Pharma A/S and 5 mentions for Erasca. Ascendis Pharma A/S's average media sentiment score of 1.34 beat Erasca's score of 0.72 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ERAS or SMMT?

Erasca is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A

Is ERAS or SMMT more profitable?

Erasca's return on equity of -35.31% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Summit Therapeutics N/A -291.24% -243.07%

Does the media refer more to ERAS or SMMT?

In the previous week, Summit Therapeutics had 3 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Summit Therapeutics and 5 mentions for Erasca. Erasca's average media sentiment score of 0.72 beat Summit Therapeutics' score of 0.39 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to ERAS or BBIO?

In the previous week, BridgeBio Pharma had 9 more articles in the media than Erasca. MarketBeat recorded 14 mentions for BridgeBio Pharma and 5 mentions for Erasca. BridgeBio Pharma's average media sentiment score of 1.00 beat Erasca's score of 0.72 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ERAS or AXSM more profitable?

Erasca has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Erasca's return on equity of -35.31% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Axsome Therapeutics -26.59% -267.16% -28.53%

Does the media prefer ERAS or AXSM?

In the previous week, Axsome Therapeutics had 8 more articles in the media than Erasca. MarketBeat recorded 13 mentions for Axsome Therapeutics and 5 mentions for Erasca. Erasca's average media sentiment score of 0.72 beat Axsome Therapeutics' score of 0.32 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ERAS or ELAN?

In the previous week, Elanco Animal Health had 9 more articles in the media than Erasca. MarketBeat recorded 14 mentions for Elanco Animal Health and 5 mentions for Erasca. Elanco Animal Health's average media sentiment score of 1.08 beat Erasca's score of 0.72 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Erasca (ERAS) Competitors

$13.18 -0.30 (-2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$13.11 -0.07 (-0.50%)

As of 07:54 PM Eastern

Compare

ERAS vs. ASND, SMMT, BBIO, AXSM, and ELAN

Should you buy Erasca stock or one of its competitors? MarketBeat compares Erasca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Erasca include Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Erasca compare to Ascendis Pharma A/S?

Erasca (NASDAQ:ERAS) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Erasca currently has a consensus target price of $18.75, indicating a potential upside of 42.26%. Ascendis Pharma A/S has a consensus target price of $295.39, indicating a potential upside of 36.26%. Given Erasca's higher possible upside, equities research analysts clearly believe Erasca is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Erasca has higher earnings, but lower revenue than Ascendis Pharma A/S. Erasca is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Ascendis Pharma A/S	$814.57M	16.60	-$258M	$8.67	25.00

Erasca has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 57.87% compared to Erasca's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

67.8% of Erasca shares are owned by institutional investors. 14.2% of Erasca shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Ascendis Pharma A/S and 5 mentions for Erasca. Ascendis Pharma A/S's average media sentiment score of 1.34 beat Erasca's score of 0.72 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Erasca on 11 of the 15 factors compared between the two stocks.

How does Erasca compare to Summit Therapeutics?

Erasca (NASDAQ:ERAS) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Erasca currently has a consensus price target of $18.75, indicating a potential upside of 42.26%. Summit Therapeutics has a consensus price target of $26.05, indicating a potential upside of 72.89%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

Erasca's return on equity of -35.31% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Summit Therapeutics	N/A	-291.24%	-243.07%

In the previous week, Summit Therapeutics had 3 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Summit Therapeutics and 5 mentions for Erasca. Erasca's average media sentiment score of 0.72 beat Summit Therapeutics' score of 0.39 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Erasca is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Erasca has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market.

67.8% of Erasca shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Erasca beats Summit Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Erasca compare to BridgeBio Pharma?

Erasca (NASDAQ:ERAS) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Erasca has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
BridgeBio Pharma	$502.08M	25.54	-$724.93M	-$3.74	N/A

Erasca has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
BridgeBio Pharma	-124.42%	N/A	-65.81%

In the previous week, BridgeBio Pharma had 9 more articles in the media than Erasca. MarketBeat recorded 14 mentions for BridgeBio Pharma and 5 mentions for Erasca. BridgeBio Pharma's average media sentiment score of 1.00 beat Erasca's score of 0.72 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

67.8% of Erasca shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Erasca presently has a consensus target price of $18.75, suggesting a potential upside of 42.26%. BridgeBio Pharma has a consensus target price of $89.59, suggesting a potential upside of 36.82%. Given Erasca's higher possible upside, equities analysts plainly believe Erasca is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

BridgeBio Pharma beats Erasca on 9 of the 14 factors compared between the two stocks.

How does Erasca compare to Axsome Therapeutics?

Erasca (NASDAQ:ERAS) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Erasca has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Axsome Therapeutics	$638.50M	18.80	-$183.17M	-$3.73	N/A

Erasca has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Erasca currently has a consensus target price of $18.75, indicating a potential upside of 42.26%. Axsome Therapeutics has a consensus target price of $251.26, indicating a potential upside of 7.69%. Given Erasca's higher possible upside, equities research analysts plainly believe Erasca is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

67.8% of Erasca shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Erasca has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Erasca's return on equity of -35.31% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

In the previous week, Axsome Therapeutics had 8 more articles in the media than Erasca. MarketBeat recorded 13 mentions for Axsome Therapeutics and 5 mentions for Erasca. Erasca's average media sentiment score of 0.72 beat Axsome Therapeutics' score of 0.32 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Axsome Therapeutics beats Erasca on 8 of the 15 factors compared between the two stocks.

How does Erasca compare to Elanco Animal Health?

Erasca (NASDAQ:ERAS) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Erasca currently has a consensus target price of $18.75, indicating a potential upside of 42.26%. Elanco Animal Health has a consensus target price of $28.20, indicating a potential upside of 14.78%. Given Erasca's higher possible upside, equities research analysts plainly believe Erasca is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Erasca has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Elanco Animal Health	-4.95%	7.42%	3.66%

In the previous week, Elanco Animal Health had 9 more articles in the media than Erasca. MarketBeat recorded 14 mentions for Elanco Animal Health and 5 mentions for Erasca. Elanco Animal Health's average media sentiment score of 1.08 beat Erasca's score of 0.72 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Elanco Animal Health	$4.72B	2.60	-$232M	-$0.50	N/A

67.8% of Erasca shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Erasca has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

Summary

Elanco Animal Health beats Erasca on 11 of the 15 factors compared between the two stocks.

Get Erasca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERAS vs. The Competition

Export

Metric	Erasca	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.19B	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	N/A	17.93	22.30	24.19
Price / Sales	N/A	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	12.55	6.63	9.84	6.72
Net Income	-$124.55M	$24.20M	$3.57B	$337.19M
7 Day Performance	5.69%	-3.24%	-1.16%	0.48%
1 Month Performance	31.41%	0.53%	3.85%	5.07%
1 Year Performance	812.11%	47.24%	27.40%	34.25%

Erasca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERAS Erasca	3.0551 of 5 stars	$13.18 -2.2%	$18.75 +42.3%	+846.0%	$4.19B	N/A	N/A	120
ASND Ascendis Pharma A/S	4.6121 of 5 stars	$224.11 -5.6%	$295.39 +31.8%	+23.3%	$14.81B	$814.57M	25.85	1,189	Positive News Short Interest Decrease High Trading Volume
SMMT Summit Therapeutics	2.1289 of 5 stars	$17.54 +0.7%	$26.05 +48.5%	-16.2%	$13.51B	N/A	N/A	110	Analyst Forecast
BBIO BridgeBio Pharma	3.6804 of 5 stars	$66.26 -3.2%	$88.90 +34.2%	+80.1%	$13.41B	$502.08M	N/A	400	Positive News Analyst Forecast
AXSM Axsome Therapeutics	2.3315 of 5 stars	$234.48 +0.7%	$251.26 +7.2%	+106.4%	$11.98B	$638.50M	N/A	380	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERAS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Erasca (ERAS) Competitors

ERAS vs. ASND, SMMT, BBIO, AXSM, and ELAN

How does Erasca compare to Ascendis Pharma A/S?

Summary

How does Erasca compare to Summit Therapeutics?

Summary

How does Erasca compare to BridgeBio Pharma?

Summary

How does Erasca compare to Axsome Therapeutics?

Summary

How does Erasca compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Erasca (ERAS) Competitors

ERAS vs. ASND, SMMT, BBIO, AXSM, and ELAN

How does Erasca compare to Ascendis Pharma A/S?

Do analysts recommend ERAS or ASND?

Which has preferable earnings & valuation, ERAS or ASND?

Which has more risk & volatility, ERAS or ASND?

Is ERAS or ASND more profitable?

Do institutionals & insiders have more ownership in ERAS or ASND?

Does the media prefer ERAS or ASND?

Summary

How does Erasca compare to Summit Therapeutics?

Do analysts recommend ERAS or SMMT?

Is ERAS or SMMT more profitable?

Does the media refer more to ERAS or SMMT?

Which has preferable earnings & valuation, ERAS or SMMT?

Which has more risk and volatility, ERAS or SMMT?

Do institutionals and insiders have more ownership in ERAS or SMMT?

Summary

How does Erasca compare to BridgeBio Pharma?

Which has preferable valuation and earnings, ERAS or BBIO?

Is ERAS or BBIO more profitable?

Does the media refer more to ERAS or BBIO?

Which has more volatility and risk, ERAS or BBIO?

Do institutionals and insiders hold more shares of ERAS or BBIO?

Do analysts recommend ERAS or BBIO?

Summary

How does Erasca compare to Axsome Therapeutics?

Which has better earnings and valuation, ERAS or AXSM?

Which has more volatility & risk, ERAS or AXSM?

Do analysts recommend ERAS or AXSM?

Do insiders & institutionals have more ownership in ERAS or AXSM?

Is ERAS or AXSM more profitable?

Does the media prefer ERAS or AXSM?

Summary

How does Erasca compare to Elanco Animal Health?

Do analysts recommend ERAS or ELAN?

Is ERAS or ELAN more profitable?

Does the media prefer ERAS or ELAN?

Which has better earnings and valuation, ERAS or ELAN?

Do insiders & institutionals have more ownership in ERAS or ELAN?

Which has more volatility & risk, ERAS or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools